Evofem Biosciences (EVFM) Research & Development (2014 - 2026)
Evofem Biosciences (EVFM) reported Research & Development of $694,000 for Q2 2026, down 7.0% from $746,000 a year earlier but up 34.0% from the prior quarter.
Powered by 
Analysis
Evofem Biosciences (EVFM) Research & Development (2014 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Evofem Biosciences' Research & Development came in at $2.05 million; for FY2025, it was -$3.45 million.
- By year, Research & Development came in at $1.85 million in FY2024 (-37.2%), $2.94 million in FY2023 (-88.3%), $25.03 million in FY2022 (-24.4%) and $33.13 million in FY2021 (+94.3%).
- Five-year quarterly Research & Development spans a low of -$5.04 million in Q1 2025 and a high of $10.39 million in Q1 2022.
- Year over year, Research & Development gained in two of the last six quarters, with growth averaging 11.5%.
- The high point for year-over-year Research & Development in five years was Q2 2025 (growth of 176.3%); the low point was Q2 2023 (a decline of 94.8%).
- Per Business Quant data, the three quarters before Q2 2026 came in at $518,000 (Q1 2026), $372,000 (Q4 2025) and $470,000 (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,171.71 Bn | 1,140.30 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 642.13 Bn | 560.65 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 501.64 Bn | 474.75 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 375.66 Bn | 330.04 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 302.79 Bn | 266.78 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 268.68 Bn | 242.37 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 242.43 Bn | 197.83 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 193.69 Bn | 167.89 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 172.47 Bn | 119.12 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Evofem Biosciences | 1.33 Mn | 1.33 Mn | 2.12 Mn | 694,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 694,000.00 |
| Mar 31, 2026 | 518,000.00 |
| Dec 31, 2025 | 372,000.00 |
| Sep 30, 2025 | 470,000.00 |
| Jun 30, 2025 | 746,000.00 |
| Mar 31, 2025 | -5.04 Mn |
| Dec 31, 2024 | 649,000.00 |
| Sep 30, 2024 | 332,000.00 |
| Jun 30, 2024 | 270,000.00 |
| Mar 31, 2024 | 594,000.00 |
| Dec 31, 2023 | 1.38 Mn |
| Sep 30, 2023 | 614,000.00 |
| Jun 30, 2023 | 402,000.00 |
| Mar 31, 2023 | 540,000.00 |
| Dec 31, 2022 | 1.69 Mn |
| Sep 30, 2022 | 5.21 Mn |
| Jun 30, 2022 | 7.74 Mn |
| Mar 31, 2022 | 10.39 Mn |
| Dec 31, 2021 | 8.66 Mn |
| Sep 30, 2021 | 8.70 Mn |
API Access
Evofem Biosciences Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EVFM&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EVFM", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EVFM&period=max&api_key=YOUR_API_KEY");
const data = await res.json();